{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:24:58Z","timestamp":1787246698281,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01835-6","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T17:27:49Z","timestamp":1782667669000},"page":"4117-4138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7454-1999","authenticated-orcid":false,"given":"Zeno","family":"Fratton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bighetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bettolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Stinco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Errichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"issue":"1","key":"1835_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","volume":"11","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, et al. Psoriasis. Nat Rev Dis Primers. 2025;11(1):45. https:\/\/doi.org\/10.1038\/s41572-025-00630-5.","journal-title":"Nat Rev Dis Primers"},{"key":"1835_CR2","doi-asserted-by":"publisher","first-page":"adv40556","DOI":"10.2340\/actadv.v104.40556","volume":"104","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Riedl E, Brunner PM, Piaserico S, Visser WI, Haustrup N, et al. Identifying predictors of PASI100 responses up to month 12 in patients with moderate-to-severe psoriasis receiving biologics in the Psoriasis Study of Health Outcomes (PSoHO). Acta Derm Venereol. 2024;104:adv40556. https:\/\/doi.org\/10.2340\/actadv.v104.40556.","journal-title":"Acta Derm Venereol."},{"issue":"6","key":"1835_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/10600280241288553","volume":"59","author":"ME Greer","year":"2025","unstructured":"Greer ME, Moran SK, Feldman SR. Bimekizumab-bkzx for the treatment of plaque psoriasis: a drug review. Ann Pharmacother. 2025;59(6):577\u201384. https:\/\/doi.org\/10.1177\/10600280241288553.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"1835_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2102388.","journal-title":"N Engl J Med"},{"issue":"10273","key":"1835_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(21)00125-2.","journal-title":"Lancet"},{"issue":"2","key":"1835_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2102383.","journal-title":"N Engl J Med"},{"issue":"6","key":"1835_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/bjd\/ljad035","volume":"188","author":"B Strober","year":"2023","unstructured":"Strober B, Tada Y, Mrowietz U, Lebwohl M, Foley P, Langley RG, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023;188(6):749\u201359. https:\/\/doi.org\/10.1093\/bjd\/ljad035.","journal-title":"Br J Dermatol"},{"key":"1835_CR8","doi-asserted-by":"publisher","first-page":"1243843","DOI":"10.3389\/fmed.2023.1243843","volume":"10","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Narcisi A, Ibba L, Balato A, Bianchi L, Brianti P, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med. 2023;10:1243843. https:\/\/doi.org\/10.3389\/fmed.2023.1243843.","journal-title":"Front Med"},{"key":"1835_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/PTT.S514249","volume":"15","author":"Z Fratton","year":"2025","unstructured":"Fratton Z, Bighetti S, Bettolini L, Maione V, Arisi M, Buligan C, et al. Real-world experience of bimekizumab in a cohort of 109 patients over 48 weeks and identification of predictive factors for an early super response and risk of adverse events. Psoriasis: Targets Ther. 2025;15:145\u201358. https:\/\/doi.org\/10.2147\/PTT.S514249.","journal-title":"Psoriasis: Targets Ther"},{"key":"1835_CR10","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1501a4893","author":"Z Fratton","year":"2025","unstructured":"Fratton Z, Maione V, Bighetti S, Bettolini L, Stinco G, Errichetti E. Real-life experience of bimekizumab in 27 obese patients with plaque-type psoriasis: a 24-week multicenter retrospective study. Dermatol Pract Concept. 2025. https:\/\/doi.org\/10.5826\/dpc.1501a4893.","journal-title":"Dermatol Pract Concept"},{"issue":"6","key":"1835_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/ijd.17657","volume":"64","author":"Z Fratton","year":"2025","unstructured":"Fratton Z, Balato A, Bighetti S, Bettolini L, Maione V, Calzavara\u2010Pinton P, et al. Real\u2010world experience using Bimekizumab in a patient cohort with plaque\u2010type psoriasis and chronic kidney disease: a 48\u2010week retrospective multicentre study. Int J Dermatol. 2025;64(6):1095\u20137. https:\/\/doi.org\/10.1111\/ijd.17657.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1835_CR12","doi-asserted-by":"publisher","first-page":"2393376","DOI":"10.1080\/09546634.2024.2393376","volume":"35","author":"D Orsini","year":"2024","unstructured":"Orsini D, Megna M, Assorgi C, Balato A, Balestri R, Bernardini N, et al. Efficacy and safety of bimekizumab in elderly patients: real-world multicenter retrospective study\u2014IL PSO (Italian landscape psoriasis). J Dermatol Treat. 2024;35(1):2393376. https:\/\/doi.org\/10.1080\/09546634.2024.2393376.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1835_CR13","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jocd.15543","volume":"22","author":"M Megna","year":"2023","unstructured":"Megna M, Battista T, Potestio L, Ruggiero A, Ventura V, Fabbrocini G, et al. A case of erythrodermic psoriasis rapidly and successfully treated with bimekizumab. J Cosmet Dermatol. 2023;22(3):1146\u20138. https:\/\/doi.org\/10.1111\/jocd.15543.","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"1835_CR14","doi-asserted-by":"publisher","first-page":"e2024052","DOI":"10.5826\/dpc.1402a52","volume":"14","author":"D Orsini","year":"2024","unstructured":"Orsini D, Malagoli P, Balato A, Bianchi L, Brianti P, Buononato D, et al. Bimekizumab for the treatment of plaque psoriasis with involvement of genitalia: a 16-week multicenter real-world experience\u2014IL PSO (Italian Landscape Psoriasis). Dermatol Pract Concept. 2024;14(2):e2024052. https:\/\/doi.org\/10.5826\/dpc.1402a52.","journal-title":"Dermatol Pract Concept"},{"issue":"12","key":"1835_CR15","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1111\/1346-8138.17962","volume":"52","author":"Y Takahashi","year":"2025","unstructured":"Takahashi Y, Hagino T, Saeki H, Fujimoto E, Kanda N. A 104-week real-world outcome of bimekizumab treatment for psoriasis: biologic-na\u00efve versus-experienced patients. J Dermatol. 2025;52(12):1856\u201363. https:\/\/doi.org\/10.1111\/1346-8138.17962.","journal-title":"J Dermatol"},{"key":"1835_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llag021","author":"E De Luca","year":"2026","unstructured":"De Luca E, Dattola A, Artosi F, Bellinato F, Bianchi L, Burlando M, et al. Long-term effectiveness of bimekizumab in plaque psoriasis: 2-year drug survival from a real-life multicentre Italian study. Clin Exp Dermatol. 2026. https:\/\/doi.org\/10.1093\/ced\/llag021.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1835_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jamadermatol.2025.5205","volume":"162","author":"CW Schwarz","year":"2026","unstructured":"Schwarz CW, Loft N, Bryld LE, Nissen CV, Ajgeiy KK, Bertelsen T, et al. Drug survival of biologics in bionaive and bioexperienced patients with psoriasis. JAMA Dermatol. 2026;162(2):166. https:\/\/doi.org\/10.1001\/jamadermatol.2025.5205.","journal-title":"JAMA Dermatol"},{"issue":"1\u20132","key":"1835_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000488586","volume":"234","author":"A Costanzo","year":"2018","unstructured":"Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G, Franchi A, et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology. 2018;234(1\u20132):1\u201312. https:\/\/doi.org\/10.1159\/000488586.","journal-title":"Dermatology"},{"key":"1835_CR19","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.21.07132-2","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Fargnoli MC, Amerio P, Argenziano G, Bardazzi F, Bianchi L, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venereol. 2022. https:\/\/doi.org\/10.23736\/S2784-8671.21.07132-2.","journal-title":"Ital J Dermatol Venereol"},{"issue":"6","key":"1835_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40261-025-01440-z","volume":"45","author":"M Esposito","year":"2025","unstructured":"Esposito M, Gisondi P, Assorgi C, Bellinato F, Brianti P, Burlando M, et al. Super responder profile under bimekizumab treatment in moderate-to-severe psoriasis: a short term real-life observation\u2014IL PSO (Italian Landscape Psoriasis). Clin Drug Investig. 2025;45(6):309\u201315. https:\/\/doi.org\/10.1007\/s40261-025-01440-z.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"1835_CR21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bjd.16776","volume":"180","author":"RB Warren","year":"2019","unstructured":"Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069\u201376. https:\/\/doi.org\/10.1111\/bjd.16776.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1835_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jid.2022.05.1094","volume":"143","author":"CQ Wang","year":"2023","unstructured":"Wang CQ, Haxhinasto S, Garcet S, Kunjravia N, Cueto I, Gonzalez J, et al. Comparison of the inflammatory circuits in psoriasis vulgaris, non-pustular palmoplantar psoriasis, and palmoplantar pustular psoriasis. J Investig Dermatol. 2023;143(1):87\u201397.e14. https:\/\/doi.org\/10.1016\/j.jid.2022.05.1094.","journal-title":"J Investig Dermatol"},{"issue":"12","key":"1835_CR23","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s13555-024-01295-w","volume":"14","author":"JF Merola","year":"2024","unstructured":"Merola JF, Gottlieb AB, Pinter A, Elewski B, Gooderham M, Warren RB, et al. Bimekizumab efficacy in high-impact areas: pooled 2-year analysis in scalp, nail, and palmoplantar psoriasis from phase 3\/3b randomized controlled trials. Dermatol Ther (Heidelb). 2024;14(12):3291\u2013306. https:\/\/doi.org\/10.1007\/s13555-024-01295-w.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"20","key":"1835_CR24","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.3390\/jcm14207412","volume":"14","author":"M Bianco","year":"2025","unstructured":"Bianco M, D\u2019Oria F, Ghezzi G, Ibba L, Di Giulio S, Valenti M, et al. Real-life effectiveness and safety of bimekizumab in plaque psoriasis involving difficult-to-treat areas: a 52-week, retrospective real-world, single-center study. J Clin Med. 2025;14(20):7412. https:\/\/doi.org\/10.3390\/jcm14207412.","journal-title":"J Clin Med"},{"issue":"1","key":"1835_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamadermatol.2025.4427","volume":"162","author":"R Ouakrat","year":"2026","unstructured":"Ouakrat R, Penso L, Jullien D, Sokol H, Sbidian E. Antibiotic use and the persistence of biologic therapies in patients with psoriasis. JAMA Dermatol. 2026;162(1):55. https:\/\/doi.org\/10.1001\/jamadermatol.2025.4427.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1835_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12866-023-02895-w","volume":"23","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhang C, Zhang Q, Yu L, Chen W, Xue Y, et al. Meta-analysis of the effects of proton pump inhibitors on the human gut microbiota. BMC Microbiol. 2023;23(1):171. https:\/\/doi.org\/10.1186\/s12866-023-02895-w.","journal-title":"BMC Microbiol"},{"key":"1835_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1711288","author":"J Chen","year":"2025","unstructured":"Chen J, Sun K, Zhang X, Chen X, Chu Y, Geng L, et al. Psoriasis and gut microbes: research advances from mechanism to therapy. Front Microbiol. 2025. https:\/\/doi.org\/10.3389\/fmicb.2025.1711288.","journal-title":"Front Microbiol"},{"key":"1835_CR28","doi-asserted-by":"publisher","first-page":"177521","DOI":"10.1016\/j.ejphar.2025.177521","volume":"998","author":"M Xue","year":"2025","unstructured":"Xue M, Deng Q, Deng L, Xun T, Huang T, Zhao J, et al. Alterations of gut microbiota for the onset and treatment of psoriasis: a systematic review. Eur J Pharmacol. 2025;998:177521. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177521.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"1835_CR29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/jdv.13979","volume":"31","author":"F Bardazzi","year":"2017","unstructured":"Bardazzi F, Lambertini M, Chessa MA, Magnano M, Patrizi A, Piraccini BM. Nail involvement as a negative prognostic factor in biological therapy for psoriasis: a retrospective study. J Eur Acad Dermatol Venereol. 2017;31(5):843\u20136. https:\/\/doi.org\/10.1111\/jdv.13979.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1835_CR30","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/jdv.20739","volume":"39","author":"L Motedayen Aval","year":"2025","unstructured":"Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, et al. Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British Association of Dermatologists Biologics and Immunomodulators Register cohort study. J Eur Acad Dermatol Venereol. 2025;39(10):1785\u201395. https:\/\/doi.org\/10.1111\/jdv.20739.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1835_CR31","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","volume":"160","author":"G Hjort","year":"2024","unstructured":"Hjort G, Schwarz CW, Skov L, Loft N. Clinical characteristics associated with response to biologics in the treatment of psoriasis. JAMA Dermatol. 2024;160(8):830. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1677.","journal-title":"JAMA Dermatol"},{"key":"1835_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00117","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00117.","journal-title":"Front Pharmacol"},{"key":"1835_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2026.2673285","author":"P Gisondi","year":"2026","unstructured":"Gisondi P, Fratton Z, Vighi da Rosa R, Bellini V, Carugno A. Unveiling the IL-17 axis: an immunometabolic bridge between psoriasis and metabolic syndrome. J Dermatol Treat. 2026. https:\/\/doi.org\/10.1080\/09546634.2026.2673285.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"1835_CR34","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jaip.2023.04.015","volume":"11","author":"SG Tangye","year":"2023","unstructured":"Tangye SG, Puel A. The Th17\/IL-17 axis and host defense against fungal infections. J Allergy Clin Immunol Pract. 2023;11(6):1624\u201334. https:\/\/doi.org\/10.1016\/j.jaip.2023.04.015.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"1835_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00403-024-03594-w","volume":"317","author":"L Potestio","year":"2024","unstructured":"Potestio L, Ruggiero A, Martora F, Megna M. Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study. Arch Dermatol Res. 2024;317(1):102. https:\/\/doi.org\/10.1007\/s00403-024-03594-w.","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"1835_CR36","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/ced\/llaf271","volume":"50","author":"G Caldarola","year":"2025","unstructured":"Caldarola G, De Luca E, Amato S, Belcastro A, Bernardini N, Bianchi L, et al. Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy. Clin Exp Dermatol. 2025;50(11):2185\u201391. https:\/\/doi.org\/10.1093\/ced\/llaf271.","journal-title":"Clin Exp Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01835-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:51Z","timestamp":1787243391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01835-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1835"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01835-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zeno Fratton, Stefano Bighetti, Luca Bettolini, Marina Venturini, Mariateresa Rossi, Andrea Carugno, Nicola Zerbinati, and Giuseppe Stinco declare that they have no competing interests. Enzo Errichetti and Mariateresa Rossi are Editorial Board members of\n                      Dermatology and Therapy\n                      . Enzo Errichetti and Mariateresa Rossi were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical standards established by the 1964 Declaration of Helsinki and its later amendments. Ethical approval was obtained from the local Ethics Committee (Comitato Etico Territoriale Lombardia 6, protocol 4710). Written informed consent to participate in the study, for the use of medical records for research purposes, and for the publication of non-identifying data was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}